In particular, combinatorial therapy venetoclax plus Beti should be considered as a challenging approach to treat those patients with a highly aggressive form of CLL, those with mutant TP53, or to enhance the efficacy of venetoclax‐base therapy in those patients where responses are partial. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.